Table 3.

Possible Treatment-Related Adverse Events of Apatinib in the Safety Population

CTCAE Grade	I,n(%)	II,n(%)	III,n(%)
Non-haematological
Fatigue	4(40%)	1(10%)	1(10%)
Anorexia	2(20%)	1(10%)	0
Vomiting	1(10%)	0	0
Diarrhea	1(10%)	0	0
Hoarseness	3(30%)	0	0
Hypertension	2(20%)	4(40%)	2(20%)
Hand-foot syndrome	4(40%)	2(20%)	2(20%)
Mucositis	3(30%)	1(10%)	0
Proteinuria	4(40%)	1(10%)	0
Hypoproteinemia	5(50%)	1(10%)	0
Hyperbilirubinaemia	2(20%)	1(20%)	0
Alanine aminotransferase increased	5(50%)	1(10%)	0
Aspartate aminotransferase increased	4(40%)	2(20%)	0
Haematological
Anaemia	2(20%)	1(10%)	0
Neutropenia	1(10%)	1(10%)	1(10%)
Thrombocytopenia	1(10%)	1(10%)	0

Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.